Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eckert & Ziegler SECHIX:EUZD 94 5-Year Yield-on-Cost % is 0.64 as of Jul. 25, 2026, which is 28% above its 10-year median of 0.50. GuruFocus rates CHIX:EUZD with a GF Score™ of 94/100 and a GF Value™ of €16.36 (Fairly Valued). Among 324 Medical Devices & Instruments companies, Eckert & Ziegler SE ranks worse than 84.57% on this metric.
Eckert & Ziegler SE's yield on cost for the quarter that ended in Mar. 2026 was 0.64.
The historical rank and industry rank for Eckert & Ziegler SE's 5-Year Yield-on-Cost % or its related term are showing as below:
CHIX:EUZd'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.04 Med: 0.5 Max: 1.4
Current: 0.64
During the past 13 years, Eckert & Ziegler SE's highest Yield on Cost was 1.40. The lowest was 0.04. And the median was 0.50.
CHIX:EUZd's 5-Year Yield-on-Cost % is ranked worse than 84.57% of 324
companies
in the Medical Devices & Instruments industry
Industry Median: 2.515
vs CHIX:EUZd: 0.64
Eckert & Ziegler SE (CHIX:EUZd) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Eckert & Ziegler SE 5-Year Yield-on-Cost % Related Terms
CHIX:EUZD vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, Eckert & Ziegler SE's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eckert & Ziegler SE 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Eckert & Ziegler SE's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Eckert & Ziegler SE's 5-Year Yield-on-Cost % falls into.
Eckert & Ziegler SE 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Eckert & Ziegler SE (CHIX:EUZD) has a 5-Year Yield-on-Cost % of 0.64 as of Jul. 25, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Eckert & Ziegler SE and its competitors. This is 28% above median its historical median of 0.50. Over the past decade, Eckert & Ziegler SE's 5-Year Yield-on-Cost % has ranged from 0.04 to 1.40. According to the industry distribution chart, Eckert & Ziegler SE ranks #274 out of 324 companies in the Medical Devices & Instruments industry, placing it in the top 84.6%.
Is Eckert & Ziegler SE's 5-Year Yield-on-Cost % too high?
Eckert & Ziegler SE's current 5-Year Yield-on-Cost % of 0.64 is 28% above median its 10-year median of 0.50. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 1.40. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.52. Eckert & Ziegler SE's value of 0.64 is 74.6% below this industry median. Based on the distribution chart, Eckert & Ziegler SE ranks #274 out of 324 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Eckert & Ziegler SE has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eckert & Ziegler SE's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Eckert & Ziegler SE ranks #274 out of 324 companies for 5-Year Yield-on-Cost %. This places Eckert & Ziegler SE in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.52. Eckert & Ziegler SE's value of 0.64 is 74.6% below this benchmark. Historically, Eckert & Ziegler SE's own 5-Year Yield-on-Cost % has ranged from 0.04 to 1.40 over the past decade. While the company's 10-year median is 0.50 vs. the industry median of 2.52, Eckert & Ziegler SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.52, based on 324 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eckert & Ziegler SE's current 5-Year Yield-on-Cost % of 0.64 is 74.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Eckert & Ziegler SE and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eckert & Ziegler SE's current 5-Year Yield-on-Cost % is 0.64, which is 28% above median its own 10-year median of 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eckert & Ziegler SE stock overvalued right now?
Based on GuruFocus' analysis, Eckert & Ziegler SE (CHIX:EUZD) is currently considered Fairly Valued. The stock's GF Value™ is €16.36, compared to a current price of €15.19 — trading 7.2% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.64, which is 28% above median its 10-year median of 0.50 and 74.6% below the Medical Devices & Instruments industry median of 2.52. Eckert & Ziegler SE's overall GF Score™ is 94/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Eckert & Ziegler SE (CHIX:EUZD), the current 5-Year Yield-on-Cost % is 0.64 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eckert & Ziegler SE (CHIX:EUZD) Overvalued in 2026?
Based on GuruFocus' analysis, Eckert & Ziegler SE stock appears to be undervalued.
The current stock price of €15.19 is trading 7.2% below its estimated GF Value™ of €16.36.
GuruFocus considers Eckert & Ziegler SE to be Fairly Valued.
Key valuation signals for CHIX:EUZD:
5-Year Yield-on-Cost %: 0.64 (28% above median its 10-year median of 0.50)
GF Value™: €16.36 vs. price of €15.19 (7.2% below fair value)
Industry Position: 74.6% below the Medical Devices & Instruments median (#274 of 324)
No single metric tells the full story. See the CHIX:EUZD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eckert & Ziegler SE is a holding company with specialised in the processing of radioisotopes and the development, production and sale of isotope technology components, radiopharmaceuticals and related products. It is an international manufacturer of isotope technology components for medical, scientific, and industrial applications. The group's products are mainly used in cancer therapy, nuclear imaging, and industrial metrology. The company's segments are Medical, Isotope Products, and Other. The majority of revenue comes from Medical segment which provides pharmaceutical-quality radioactive ingredients and markets products for the treatment and diagnosis of cancers. Geographically, the company generates a majority of its revenue from Europe and then North America, Asia/Pacific, and other.
94GF Score
Get the complete analysis for CHIX:EUZD
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:EUZD has been successfully added to your 
